SIBN
SI-BONE, Inc.
Next earnings Aug 3, 2026 · consensus $-0.16 EPS, $56.4M rev
Last earnings -5.4% on 2026-05-11
$17.33
▲ +3.40%$17.33▲ +4.90%
over 1Y
L $11.61EODHDH $21.40
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.4%
1W+9.5%
1M+19.8%
3M+41.0%
YTD-12.4%
1Y+4.9%
Hold
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 15 analysts
Buy
Strong 20% revenue growth and 79.6% gross margins, but still unprofitable at 3.7x sales — a quality compounder priced for patience.
Revenue $201M · FY2025
SI-BONE is executing a textbook med-device growth playbook: FY2025 revenue grew 20.2% to $201M, with gross margin at a software-like 79.6% and the loss narrowing for the fourth straight year (-$56.6M → -$18.9M from FY2021 to FY2025). The MD&A confirms the commercial flywheel is real — 140,000+ procedures performed since 2009, U.S. sales force expanded to 89 TSMs / 83 CSSs / 320 third-party agents (up from 87/71/252), and three FDA-designated breakthrough device platforms now extend the franchise from SI-joint fusion into thoracolumbar fixation and pelvic trauma. ASC/OBL mix above 33% is a positive site-of-service tailwind that should aid utilization without proportionate sales-force cost.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $90.2M | $106M | $139M | $167M | $201M |
| Gross profit | $79.7M | $90.7M | $109M | $132M | $160M |
| Operating income | -$51.7M | -$59.6M | -$46.9M | -$35.2M | -$22.3M |
| Net income | -$56.6M | -$61.3M | -$43.3M | -$30.9M | -$18.9M |
| Diluted EPS | -$1.71 | -$1.79 | -$1.13 | -$0.75 | -$0.44 |
| Net margin | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$759M
EV / EBITDA—
EV / Sales3.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.5%
FCF yield-1.2%
Quality & risk
ROIC (est.)-8.3%
Free cash flow-$9.09M
Total debt$35.6M
Net cash$6.67M
Altman Z-Score6.38 safe
Piotroski F-Score6/9
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+4.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Material agreement2026-06-08
Material agreement + new debt facility; annual meeting vote results disclosed
- 8-K Earnings results2026-05-11
Q1 2026 10-Q filed; growth + path-to-profitability story continues
- 10-Q Quarterly report2026-05-11
Q1 2026 10-Q filed; growth + path-to-profitability story continues
- DEF 14A Proxy statement2026-04-21
2026 proxy: board slate, exec comp, auditor ratification
- 10-K Annual report2026-02-24
FY25 revenue +20% to $201M; loss narrowed 39% to -$18.9M; new SJ HQ lease
- 8-K Officer / director change2026-02-23
FY2025 earnings + material agreement + officer change announced
- 8-K Earnings results2026-01-12
Preliminary Q4/FY25 results pre-announced, likely at JPM healthcare conference
- 8-K Officer / director change2025-11-10
Q3 2025 10-Q: sales force scaling, sustained top-line growth
- 10-Q Quarterly report2025-11-10
Q3 2025 10-Q: sales force scaling, sustained top-line growth
Recent filings
all on EDGAR ↗4Period ending 2026-06-042026-06-09open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗8-KPeriod ending 2026-06-042026-06-08open ↗4Period ending 2026-05-282026-06-01open ↗144Filing2026-05-29open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗
Frequently asked
- Is SI-BONE, Inc. (SIBN) a buy?
- SIBN currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Strong 20% revenue growth and 79.6% gross margins, but still unprofitable at 3.7x sales — a quality compounder priced for patience.
- What is SI-BONE, Inc.'s quality score?
- SIBN scores 59.509803921568626/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001459839, latest 10-Q filed 2026-05-11) · EODHD · analysis by claude-code · as of 6/25/2026, 3:14:09 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.